Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
Fabio EfficaceFausto CastagnettiBruno MartinoMassimo BrecciaMariella D'AddaEmanuele AngelucciFabio StagnoFrancesco CottoneAlessandra MalatoElena TrabacchiSilvana Franca CapalboMarco GobbiGiuseppe VisaniMarzia SalvucciIsabella CapodannoPatrizia TosiMario TiribelliAnna Rita ScortechiniLuciano LevatoElena MainoGianni BinottoGabriele GugliottaMarco VignettiMichele BaccaraniGianantonio RostiPublished in: Cancer (2018)
For most patients, HRQOL improvements with nilotinib occur during the early phase of therapy and are maintained over time. Also, a more systematic HRQOL evaluation during the diagnostic workup of CML may help to predict clinical outcomes. Cancer 2018;124:2228-37. © 2018 American Cancer Society.